There’s a question I get asked fairly often in practice, usually from people who’ve already done one gut test and are wondering whether to do the other: if I’ve already had a GI-MAP, do I need the OAT? Or conversely: my OAT showed some elevated markers — should I also be doing a stool test? The answer in both cases is often yes, and the reason comes down to what each test can and cannot see. They’re not duplicates. They’re not even close to the same test. They measure gut function from completely different vantage points, and what they reveal when read together is substantially more than the sum of each read alone.
What Each Test Actually Measures
The GI-MAP is a stool test using quantitative PCR — the same technology used in COVID testing — to identify and quantify specific organisms in the gut. It tells you what is present: which bacteria, which parasites, which fungi, which viruses. It tells you how much is present — not just positive or negative, but actual load expressed in DNA copies. And through its functional markers, it tells you something about the state of the gut environment: is the barrier intact (zonulin, secretory IgA), is there active inflammation (calprotectin, lactoferrin), is fat digestion working (pancreatic elastase).
What the GI-MAP cannot tell you is what those organisms are doing to the rest of your body. It can confirm that Clostridia species are elevated. It cannot tell you how much HPHPA — the neurotoxic Clostridia metabolite — is circulating in your system and inhibiting your dopamine conversion. It can detect Candida. It cannot quantify the arabinose that Candida is producing and what that’s doing to your mitochondrial function. It can flag dysbiosis. It cannot show you what that dysbiosis is producing metabolically or where those metabolic products are ending up.
The OAT fills exactly this gap. It measures organic acids in urine — the metabolic byproducts of what organisms in the gut are producing, what cellular energy systems are doing with those compounds, and what the downstream effects are on neurotransmitter production, B-vitamin function, detoxification capacity, and mitochondrial output. It’s measuring consequences and metabolic footprints rather than organisms themselves.
| What you want to know | GI-MAP | OAT |
|---|---|---|
| Which organisms are present | ✓ Direct identification | Indirect — metabolite signatures only |
| Organism load / quantity | ✓ Quantitative PCR | ✗ Not measured |
| Gut barrier integrity | ✓ Zonulin, sIgA | ✗ Not measured directly |
| Active gut inflammation | ✓ Calprotectin, lactoferrin | ✗ Not measured |
| What organisms are producing | ✗ Not measured | ✓ Metabolite byproducts |
| Mitochondrial function | ✗ Not measured | ✓ Krebs cycle acids |
| Neurotransmitter metabolism | ✗ Not measured | ✓ HVA, 5-HIAA, VMA |
| B-vitamin functional status | ✗ Not measured | ✓ B12, B6, folate markers |
| Yeast/Candida presence | ✓ Species identified | ✓ Arabinose (metabolite) |
| Clostridia presence | ✓ Species identified | ✓ HPHPA (metabolite) |
Where the Tests Cross-Read Each Other
The most clinically useful aspect of running both is that specific findings on one test explain specific findings on the other. This cross-referencing is where combined testing earns its cost. Let me give you the specific patterns I find most significant.
OAT: elevated HPHPA
OAT: elevated arabinose
OAT: elevated oxalate, low B vitamins
OAT: elevated Krebs cycle acids
The Yeast and Microbial OAT Markers — Why They Add to the GI-MAP, Not Duplicate It
One of the most common misconceptions I encounter is that if the GI-MAP checked for Candida and found it, running the OAT for arabinose tells you nothing new. This misunderstands what each test is measuring. The GI-MAP identifies the organism and its load in stool. Arabinose on the OAT measures the metabolic output of that organism in urine — which reflects systemic exposure, not just gut presence.
You can have Candida at a moderate load on the GI-MAP and very high arabinose on the OAT, which tells you the yeast is metabolically very active and its products are reaching systemic circulation in significant quantities. Conversely, you can have elevated arabinose on the OAT with Candida below the detection threshold on the GI-MAP — because the yeast is producing arabinose in the small intestine (which the GI-MAP stool test doesn’t sample effectively) rather than the large intestine. The OAT catches small intestinal yeast that the GI-MAP misses by design, because it’s measuring what the yeast is producing systemically rather than what’s present at the point of stool collection.
The GI-MAP reads what’s in the large intestine at the point of collection. The OAT reads what the entire gut ecosystem has been producing over the preceding days. They’re looking at the same gut from different windows — and sometimes different windows show different things.
The same logic applies to Clostridia. HPHPA on the OAT can be elevated without Clostridia difficile appearing on the GI-MAP, because HPHPA is produced by several Clostridia species — not all of which are included in every GI-MAP panel, and some of which exist at loads that fall below the quantitative threshold for flagging but are still metabolically significant. An elevated HPHPA is the functional readout; the GI-MAP gives you the species-level detail that tells you which organisms are responsible.
The Clinical Scenarios Where Combined Testing Changes Management
Not every person needs both. In the TDG five-test programme, they run together as standard precisely because the cross-reading is so consistently informative. But for someone considering gut testing outside the full programme, here are the clinical presentations where I think combined testing is most clearly worth it:
Unexplained mood and cognitive symptoms alongside gut problems. When someone has both gut dysbiosis symptoms and significant brain fog, low mood, poor concentration, or anxiety — and especially when those neurological symptoms seem disproportionate to the gut symptoms — the OAT’s neurotransmitter markers (HVA, 5-HIAA, VMA) alongside the GI-MAP’s microbial findings often tell a unified story. The cognitive symptoms aren’t separate from the gut problem; they’re downstream of it. But you need both tests to see that connection clearly.
Fatigue that doesn’t improve with gut treatment. Someone who has done a round of gut work — antimicrobials, probiotics, dietary changes — and still has significant fatigue despite improving gut symptoms. The OAT is what tells you whether the mitochondrial impact of the original dysbiosis has been addressed, or whether Krebs cycle function is still impaired even after the organisms driving it have been reduced.
Complex dysbiosis with multiple elevated pathogens. When the GI-MAP shows multiple elevated markers — Clostridia, yeast, parasites, bacterial pathogens — the OAT helps prioritise. If HPHPA is significantly elevated, the Clostridia picture has the most systemic impact and should be addressed first. If arabinose is the dominant OAT finding, yeast is the priority. The GI-MAP tells you what’s there; the OAT helps you sequence what to address in what order.
Children with gut-brain presentations. Autism spectrum presentations, ADHD, sensory processing differences, and anxiety in children frequently involve elevated HPHPA and arabinose on the OAT alongside dysbiosis on the GI-MAP. The gut-brain connection in neurodevelopmental contexts is one of the areas where combined testing provides the clearest clinical picture, because the mechanism — gut organisms producing neurotransmitter-disrupting metabolites — is directly visible across both tests simultaneously.
When the OAT shows microbial markers but the GI-MAP hasn’t been done. If someone has an existing OAT showing elevated arabinose or HPHPA without a GI-MAP, the GI-MAP is the logical next step. The OAT is telling you something significant is happening in the gut. The GI-MAP tells you specifically what.
The Sequencing Question — Which to Run First?
If budget requires choosing one initially, run the GI-MAP first. The reasons are practical: the GI-MAP answers the question of what is present with greater specificity and guides the initial protocol more directly. The OAT then runs either alongside the initial treatment phase (to get a baseline of metabolic impact) or after a first round of gut work (to assess whether the systemic consequences of the dysbiosis have resolved alongside the organisms themselves).
That said, in the TDG programme context they run simultaneously because the baseline cross-reading is where the real clinical value sits. A GI-MAP showing moderate Clostridia elevation looks very different clinically when the OAT also shows significantly elevated HPHPA than when the OAT HPHPA is within range — one requires urgent neurological support as part of the protocol, the other doesn’t. That distinction isn’t available if the tests are run six months apart.
The principle behind running these tests together is the same principle that runs through everything in the TDG approach: no single test tells the whole story, and the most clinically useful information sits at the intersection of multiple data points viewed simultaneously. The GI-MAP without the OAT tells you what organisms are present but not what they’re doing. The OAT without the GI-MAP shows you the metabolic consequences without identifying the source. Together, they read each other — and in doing so, they give you both the diagnosis and the treatment priority in the same result.